Medios AG: Successful financial year 2020
DGAP-News: Medios AG / Key word(s): Annual Results/Forecast
Berlin, March 31, 2021 - Medios AG ("Medios"), the leading provider of Specialty Pharma solutions in Germany, has published its Annual Report 2020. In the reporting year 2020, group sales increased by 21.2% to €626.5 million (previous year: €516.8 million) compared to the same period of the previous year, thus reaching a record level despite a difficult market environment. However, due to the COVID 19-related effects, consolidated earnings did not reach the previous year's level: Consolidated earnings before interest, taxes, depreciation and amortization (EBITDA)* adjusted for extraordinary expenses amounted to €15.1 million (previous year: €17.7 million) and consolidated earnings before taxes (EBT)* adjusted for extraordinary expenses were around €12.0 million (previous year: €16.2 million). Medios carried out, or prepared, two forward-looking acquisitions in the year under review: Kölsche Blister GmbH expanded the company's business model to include the attractive service of blister packaging. With the acquisition of the specialized pharmaceutical wholesaler Cranach Pharma AG, which has since been completed, Medios has significantly strengthened its position as a full-range supplier in the Specialty Pharma segment. For the current fiscal year, Medios expects a significant increase in sales, for the first time exceeding one billion, to €1.2 billion, as well as a substantial jump in earnings.
Both operating segments with dynamic sales growth
The Patient-Specific Therapies business segment generated sales of €61.9 million in fiscal 2020, an increase of 22.7% over the previous year (previous year: €50.4 million). This was due in particular to the significant increase of individualized manufacturing units to over 100,000 in 2020 and the further diversification of the indication areas.
Matthias Gaertner, CEO and CFO of Medios AG: "In a difficult and challenging environment, we continued to grow double-digit in 2020. Despite the Corona-related special effects in the second quarter, we were able to close the 2020 financial year with a very good fourth quarter. We have also already set the course for a successful and sustainable continuation of our growth path: In addition to organic growth, we are focusing in particular on further acquisitions with a focus on patient-specific therapies. In addition, we want to help shape the digitization of the healthcare sector - also with our innovative online trading platform mediosconnect. With the development of a comprehensive ESG strategy, we will put an exclamation mark on sustainability."
Medios' activities with regard to environmental, social and governance aspects (ESG) are described in a voluntary Nonfinancial Consolidated Statement in the annual report, for the first time. In addition, by joining the United Nations Global Compact in March 2021, Medios voluntarily committed itself to complying with the ten universal principles and sustainability goals of the world's largest initiative for responsible corporate governance.
Positive outlook 2021
Medios AG's Annual Report 2020 is available for download on the Investor Relations website https://medios.ag/investor-relations/reporting-center.
*EBITDA is defined as net earnings before interest, income taxes, depreciation and amortization. EBT is defined as net earnings before income taxes. AdjustedEBITDA and adjustedEBT are each adjusted for extraordinary expenses for stock options, M&A activities and amortization of the customer base.
About Medios AG
Medios AG is Germany's first listed Specialty Pharma company and member of the SDAX selection index (Prime Standard) (ISIN: DE000A1MMCC8).
|Phone:||+49 30 232 566 - 800|
|Fax:||+49 30 232 566 - 801|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf|
|EQS News ID:||1179718|
|End of News||DGAP News Service|